|
28 Jul 2021 |
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
|
|
28 Jul 2021 |
Ipsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis Pathway
|
|
28 Jul 2021 |
DiosCURE Announces Exclusive Worldwide License Agreement for Best-in-Class Nanobodies Against COVID-19
|
|
28 Jul 2021 |
Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
|
|
28 Jul 2021 |
Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose
|
|
28 Jul 2021 |
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
|
|
28 Jul 2021 |
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
|
|
28 Jul 2021 |
Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)
|
|
28 Jul 2021 |
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH
|
|
28 Jul 2021 |
AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
|
|
27 Jul 2021 |
Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
|
|
27 Jul 2021 |
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
|
|
27 Jul 2021 |
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
|
|
27 Jul 2021 |
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
|
|
27 Jul 2021 |
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
|
|
27 Jul 2021 |
Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem
|
|
26 Jul 2021 |
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
|
|
26 Jul 2021 |
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
|
|
26 Jul 2021 |
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
|
|
26 Jul 2021 |
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021
|
